Pfizer has reiterated its commitment to developing an orphan and rare diseases franchise by acquiring the private US company FoldRx Pharmaceuticals. The two companies did not disclose the financial terms of the acquisition, though Pfizer will make ...
Ono Pharmaceutical has acquired exclusive development and commercialisation rights in Japan to Concordia Pharmaceuticals' direct Ras inhibitor salirasib, which it will develop initially for pancreatic cancer.
The Japanese firm will pay undisclosed ...
Bayer's dermatology subsidiary, Intendis, has licensed rights to Kythera Biopharmaceuticals' lead product candidate, ATX-101, outside North America. Bayer paid $43 million up front and could pay up to an additional $330 million for development, ...
HUYA Bioscience International has entered into a collaborative agreement with another academic research group in China, this time with the Sun Yat-sen University in Guangzhou.
The tie-up gives HUYA access to and first review of certain novel ...
Meda of Sweden is to acquire the US speciality pharma company Alaven Pharmaceutical to enhance its US marketing capabilities and expand its therapeutic focus to include both gastroenterology and women's health, areas it already operates in outside ...
